218 related articles for article (PubMed ID: 23672526)
21. Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score.
Souza-Nogueira A; Camargo AE; Remondi FA; Paoliello MM; Richter RJ; Furlong CE; Barbosa DS; Maes M; Moreira EG
Arch Endocrinol Metab; 2016 Oct; 60(5):426-435. PubMed ID: 27812605
[TBL] [Abstract][Full Text] [Related]
22. Long-term ocular consequences of sulfur mustard in lung-injured war veterans.
Ghasemi H; Ghazanfari T; Yaraee R; Rafii AB; Pourfarzam S; Soroush MR; Babaei M; Faghihzadeh S; Naghizadeh MM; Hassan ZM
Cutan Ocul Toxicol; 2012 Mar; 31(1):33-7. PubMed ID: 21774734
[TBL] [Abstract][Full Text] [Related]
23. Pro-oxidant-antioxidant balance in Iranian veterans with sulfur mustard toxicity and different levels of pulmonary disorders.
Nobakht M Gh BF; Oskouie AA; Aliannejad R; Rezaei-Tavirani M; Tavallaie S; Baghban AA; Taheri S; Keramati MR; Alamdari DH
Drug Chem Toxicol; 2016 Oct; 39(4):362-6. PubMed ID: 26679093
[TBL] [Abstract][Full Text] [Related]
24. PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients.
de Souza JA; Menin A; Lima LO; Smiderle L; Hutz MH; Van Der Sand CR; Van Der Sand LC; Ferreira ME; Pires RC; Almeida S; Fiegenbaum M
Clin Biochem; 2015 Nov; 48(16-17):1039-44. PubMed ID: 26079344
[TBL] [Abstract][Full Text] [Related]
25. The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease.
Mohamed RH; Mohamed RH; Karam RA; Abd El-Aziz TA
Clin Biochem; 2010 Apr; 43(6):553-8. PubMed ID: 20026099
[TBL] [Abstract][Full Text] [Related]
26. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease.
Kerkeni M; Addad F; Chauffert M; Chuniaud L; Miled A; Trivin F; Maaroufi K
Clin Biochem; 2006 Aug; 39(8):821-5. PubMed ID: 16875684
[TBL] [Abstract][Full Text] [Related]
27. Serum profiles of matrix metalloproteinases and their tissue inhibitors in long-term pulmonary complication induced by sulfur mustard: Sardasht-Iran Cohort Study (SICS).
Kiani A; Mostafaie A; Shirazi FH; Ghazanfari T
Int Immunopharmacol; 2013 Nov; 17(3):964-7. PubMed ID: 23370298
[TBL] [Abstract][Full Text] [Related]
28. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
[TBL] [Abstract][Full Text] [Related]
29. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
30. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation.
Mehdi MM; Rizvi SI
Arch Med Res; 2012 Aug; 43(6):438-43. PubMed ID: 22959975
[TBL] [Abstract][Full Text] [Related]
31. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
Sarandol A; Sarandol E; Eker SS; Karaagac EU; Hizli BZ; Dirican M; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1103-8. PubMed ID: 16716479
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase-1 genetic polymorphisms and susceptibility to DNA damage in workers occupationally exposed to organophosphate pesticides.
Singh S; Kumar V; Thakur S; Banerjee BD; Rautela RS; Grover SS; Rawat DS; Pasha ST; Jain SK; Ichhpujani RL; Rai A
Toxicol Appl Pharmacol; 2011 Apr; 252(2):130-7. PubMed ID: 21291901
[TBL] [Abstract][Full Text] [Related]
33. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of pon1 and pon2 genes in hemodialyzed patients.
Rajković MG; Barišić K; Juretić D; Grubišić TŽ; Flegar-Meštrić Z; Rumora L
Clin Biochem; 2011 Aug; 44(12):964-8. PubMed ID: 21620813
[TBL] [Abstract][Full Text] [Related]
35. PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy.
Pérez-Herrera N; May-Pech C; Hernández-Ochoa I; Castro-Mañé J; Rojas-García E; Borja-Aburto VH; Castillo-Burguete T; Quintanilla-Vega B
Exp Mol Pathol; 2008 Oct; 85(2):129-34. PubMed ID: 18582459
[TBL] [Abstract][Full Text] [Related]
36. Can paraoxonase 1 polymorphisms (L55 M and Q192 R) protect children with type 1 diabetes against lipid abnormalities?
Fekih O; Triki S; Hellara I; Neffati F; Rejeb J; Ommezzine A; Chouchane S; Guediche MN; Bouslama A; Najjar MF
J Clin Lipidol; 2014; 8(3):249-55. PubMed ID: 24793345
[TBL] [Abstract][Full Text] [Related]
37. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease.
Ding J; Chen Q; Zhuang X; Feng Z; Xu L; Chen F
Med Sci Monit; 2014 Nov; 20():2421-9. PubMed ID: 25420483
[TBL] [Abstract][Full Text] [Related]
38. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
[TBL] [Abstract][Full Text] [Related]
39. LDL density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease.
Cagnin A; Leon A; Vianello D; Colavito D; Favaretto S; Zarantonello G; Stecca A; Ermani M; Zambon A
J Alzheimers Dis; 2013; 34(2):377-85. PubMed ID: 23207490
[TBL] [Abstract][Full Text] [Related]
40. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
Yavuz DG; Yüksel M; Deyneli O; Ozen Y; Aydin H; Akalin S
Clin Endocrinol (Oxf); 2004 Oct; 61(4):515-21. PubMed ID: 15473886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
